Welcome to our dedicated page for SCRIBE THERAPEUTICS news (Ticker: SCTX), a resource for investors and traders seeking the latest updates and insights on SCRIBE THERAPEUTICS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SCRIBE THERAPEUTICS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SCRIBE THERAPEUTICS's position in the market.
Scribe Therapeutics (SCTX) reported second quarter 2026 results and detailed major clinical, financing and grant milestones.
The company initiated a first-in-human Phase 1 trial in Australia for STX-1150, an in vivo CRISPR-based epigenetic PCSK9 silencing therapy for LDL-C lowering, with initial single-ascending-dose data expected in the first half of 2027. More than $25.7 million in non-dilutive CIRM grants were awarded to advance STX-1200 for Lp(a) and STX-1400 for triglycerides toward potential clinical entry as early as 2027. Scribe completed an upsized IPO and concurrent private placement to Sanofi, raising $155.5 million in aggregate gross proceeds and listing on Nasdaq under “SCTX.”
As of June 30, 2026, cash, cash equivalents and marketable securities were $43.0 million, with approximately $140.6 million of additional net proceeds from the July 2026 IPO and private placement expected to fund operations into the first half of 2029. Q2 2026 collaboration revenue was $1.9 million versus $4.9 million a year earlier, R&D expenses declined to $8.8 million from $13.9 million, and net loss narrowed to $6.5 million from $9.9 million.
Scribe Therapeutics (Nasdaq:SCTX) will participate in three investor events in September–October 2026. Management joins the Wells Fargo Healthcare Conference in Boston on Sept. 9 at 8:00 AM ET, the H.C. Wainwright 28th Annual Global Investment Conference in New York on Sept. 15, and the Cell & Gene Meeting on the Mesa in Phoenix on Oct. 5 at 5:15 PM MT.
Scribe Therapeutics (Nasdaq: SCTX) closed its upsized initial public offering of 9,867,000 common shares, including 1,287,000 additional shares from the underwriters’ fully exercised option, at $15.00 per share. All shares were issued by the company, whose stock began trading on the Nasdaq Global Market on July 24, 2026 under ticker SCTX.
According to Scribe Therapeutics, aggregate gross proceeds from the IPO and a concurrent private placement totaled approximately $155.51 million before underwriting discounts and commissions. The private placement comprised 500,000 shares sold to Sanofi at the IPO price. Leerink Partners, Goldman Sachs, Guggenheim Securities and Wells Fargo Securities acted as joint book-running managers.
Scribe Therapeutics (Nasdaq: SCTX) priced its upsized initial public offering of 8,580,000 common shares at $15.00 per share, at the high end of the indicated range, for expected gross proceeds of $128.7 million before expenses. All shares are being sold by Scribe Therapeutics, and the company granted underwriters a 30-day option to buy up to 1,287,000 additional shares at the IPO price, less underwriting discounts and commissions.
The shares are expected to begin trading on the Nasdaq Global Market on July 24, 2026 under the symbol SCTX, with closing anticipated on July 27, 2026, subject to customary conditions. Scribe Therapeutics also agreed to sell 500,000 shares at $15.00 per share in a concurrent private placement to Sanofi, expected to close on the same date, contingent on the IPO closing.